67531-69-5

Upstream product

• 17408-16-1 3'-nitropropiophenone 

Downstream Products

• 181929-85-1 {3-[1-(4-Hydroxy-2-oxo-5,6,7,8,9,10,11,12-octahydro-2H-cyclodeca[b]pyran-3-yl)-propyl]-phenyl}-carbamic acid benzyl ester 
• 166334-81-2 {3-[1-(4-Hydroxy-2-oxo-5,6,7,8,9,10-hexahydro-2H-cycloocta[b]pyran-3-yl)-propyl]-phenyl}-carbamic acid benzyl ester 
• 181929-83-9 {3-[1-(4-Hydroxy-2-oxo-2,5,6,7,8,9-hexahydro-cyclohepta[b]pyran-3-yl)-propyl]-phenyl}-carbamic acid benzyl ester 
• 181929-82-8 {3-[1-(4-Hydroxy-2-oxo-5,6,7,8-tetrahydro-2H-chromen-3-yl)-propyl]-phenyl}-carbamic acid benzyl ester 
• 181929-46-4 {3-[1-(4-Hydroxy-2-oxo-2,5,6,7-tetrahydro-cyclopenta[b]pyran-3-yl)-propyl]-phenyl}-carbamic acid benzyl ester 
• 166334-82-3 2H-Cycloocta[b]pyran-2-one, 3-[1-(3-aminophenyl)propyl]-5,6,7,8,9,10-hexahydro-4-hydroxy- 
• 181930-01-8 3-[1-(3-Amino-phenyl)-propyl]-4-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyran-2-one 
• 166337-56-0 [3-(1-Hydroxy-propyl)-phenyl]-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Methods of using norfluoxetine

The invention encompasses methods of using racemic and enantiomerically pure norfluoxetine, as well as pharmaceutical compositions, pharmaceutical unit dosage forms, and kits comprising racemic and enantiomerically pure norfluoxetine. In particular, the i

Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: Exploring the impact of ring size on structure-activity relationships

Previously, 3-substituted cycloalkylpyranones, such as 2d, have proven to be effective inhibitors of HIV protease. In an initial series of 3-(1- phenylpropyl) derivatives with various cycloalkyl ring sizes, the cyclooctyl analog was the most potent. We be